Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Brandon S Imber, Andrew L Lin, Zhigang Zhang, Krishna Nand Keshavamurthy, Amy Robin Deipolyi, Kathryn Beal, Marc A Cohen, Viviane Tabar, Lisa M DeAngelis, Eliza B Geer, T Jonathan Yang, Robert J Young
CONTEXT: Pituitary adenomas (PA) are often irregularly shaped, particularly posttreatment. There are no standardized radiographic criteria for assessing treatment response, substantially complicating interpretation of prospective outcome data. Existing imaging frameworks for intracranial tumors assume perfectly spherical targets and may be suboptimal. OBJECTIVE: To compare a three-dimensional (3D) volumetric approach against accepted surrogate measurements to assess PA posttreatment response (PTR)...
September 1, 2019: Journal of the Endocrine Society
#22
JOURNAL ARTICLE
Babak B Navi, Ryna Mathias, Carla P Sherman, Julia Wolfe, Hooman Kamel, Scott T Tagawa, Ashish Saxena, Allyson J Ocean, Costantino Iadecola, Lisa M DeAngelis, Mitchell S V Elkind, Heather Hull, Glen C Jickling, Frank R Sharp, Bradley P Ander, Boryana Stamova
Background and Purpose- Comorbid cancer is common in patients with acute ischemic stroke (AIS). As blood mRNA profiles can distinguish AIS mechanisms, we hypothesized that cancer-related AIS would have a distinctive gene expression profile. Methods- We evaluated 4 groups of 10 subjects prospectively enrolled at 3 centers from 2009 to 2018. This included the group of interest with active solid tumor cancer and AIS and 3 control groups with active cancer only, AIS only, or vascular risk factors only. Subjects in the AIS-only and cancer-only groups were matched to subjects in the cancer-stroke group by age, sex, and cancer type (if applicable)...
November 2019: Stroke; a Journal of Cerebral Circulation
#23
JOURNAL ARTICLE
Michael Offin, Daniel Feldman, Ai Ni, Mackenzie L Myers, W Victoria Lai, Elena Pentsova, Adrienne Boire, Mariza Daras, Emmet J Jordan, David B Solit, Maria E Arcila, David R Jones, James M Isbell, Kathryn Beal, Robert J Young, Charles M Rudin, Gregory J Riely, Alexander Drilon, Viviane Tabar, Lisa M DeAngelis, Helena A Yu, Mark G Kris, Bob T Li
BACKGROUND: Mutations in human epidermal growth factor receptor 2 (HER2; also known as ERBB2) are found in approximately 2% of lung adenocarcinomas. The frequency and clinical course of brain metastases in this oncogenic subset are ill defined. METHODS: Baseline and subsequent development of brain metastases was evaluated in consecutive patients with HER2-mutant (n = 98), epidermal growth factor receptor (EGFR)-mutant (n = 200), and KRAS-mutant lung cancers (n = 200)...
August 30, 2019: Cancer
#24
JOURNAL ARTICLE
Denise D Correa, Erica Braun, Maria Kryza-Lacombe, Ka-Wai Ho, Anne S Reiner, Katherine S Panageas, Joachim Yahalom, Craig S Sauter, Lauren E Abrey, Lisa M DeAngelis, Antonio Omuro
INTRODUCTION: The standard treatment for primary central nervous system lymphoma (PCNSL) involves induction methotrexate-based chemotherapy with or without consolidation whole brain radiotherapy (WBRT). As WBRT carries a substantial risk for cognitive impairment, alternative consolidation treatments have been used to reduce neurotoxicity, including reduced-dose WBRT (rdWBRT) or high-dose chemotherapy with autologous stem cell transplant (HDC-ASCT). In this study, we characterized cognitive functions in PCNSL patients achieving long-term remission following rdWBRT or HDC-ASCT...
September 2019: Journal of Neuro-oncology
#25
JOURNAL ARTICLE
Thomas J Kaley, Katherine S Panageas, Ingo K Mellinghoff, Craig Nolan, Igor T Gavrilovic, Lisa M DeAngelis, Lauren E Abrey, Eric C Holland, Andrew B Lassman
PURPOSE: Perifosine (PRF) is an oral alkylphospholipid with antineoplastic effects and reasonable tolerability. It inhibits signaling through the PI3/AKT axis and other cascades of biologic importance in glioblastoma, and has promising pre-clinical activity in vitro and in vivo. Therefore, we conducted a phase II open-label single-arm clinical trial of perifosine for patients with recurrent glioblastoma (GBM). METHODS: We planned to accrue up to 30 adults with recurrent GBM with a minimum Karnofsky Performance Status of 50 following radiotherapy but without other restrictions on the number or types of prior therapy...
July 19, 2019: Journal of Neuro-oncology
#26
JOURNAL ARTICLE
Philip Jonsson, Andrew L Lin, Robert J Young, Natalie M DiStefano, David M Hyman, Bob T Li, Michael F Berger, Ahmet Zehir, Marc Ladanyi, David B Solit, Angela G Arnold, Zsofia K Stadler, Diana Mandelker, Michael E Goldberg, Juliann Chmielecki, Maryam Pourmaleki, Shahiba Q Ogilvie, Shweta S Chavan, Andrew T McKeown, Malbora Manne, Allison Hyde, Kathryn Beal, T Jonathan Yang, Craig P Nolan, Elena Pentsova, Antonio Omuro, Igor T Gavrilovic, Thomas J Kaley, Eli L Diamond, Jacqueline B Stone, Christian Grommes, Adrienne Boire, Mariza Daras, Anna F Piotrowski, Alexandra M Miller, Philip H Gutin, Timothy A Chan, Viviane S Tabar, Cameron W Brennan, Marc Rosenblum, Lisa M DeAngelis, Ingo K Mellinghoff, Barry S Taylor
PURPOSE: The genomic landscape of gliomas has been characterized and now contributes to disease classification, yet the relationship between molecular profile and disease progression and treatment response remain poorly understood. Experimental Design: We integrated prospective clinical sequencing of 1,004 primary and recurrent tumors from 923 glioma patients with clinical and treatment phenotypes. RESULTS: Thirteen percent of glioma patients harbored a pathogenic germline variant, including a subset associated with heritable genetic syndromes and variants mediating DNA repair dysfunctions (29% of the total) that were associated with somatic biallelic inactivation and mechanism-specific somatic phenotypes...
September 15, 2019: Clinical Cancer Research
#27
JOURNAL ARTICLE
Mary Jane Lim-Fat, Wenya Linda Bi, Janet Lo, Eudocia Quant Lee, Manmeet S Ahluwalia, Tracy T Batchelor, Susan M Chang, E Antonio Chiocca, Ugonma Chukwueke, Timothy F Cloughesy, Howard Colman, Lisa M Deangelis, Evanthia Galanis, Mark R Gilbert, John F De Groot, Andrew B Lassman, Linda M Liau, Warren Mason, J Ricardo McFaline-Figueroa, Minesh P Mehta, Ingo K Mellinghoff, L Burt Nabors, Lakshmi Nayak, David A Reardon, Patrick Y Wen
No abstract text is available yet for this article.
September 1, 2019: Neurosurgery
#28
JOURNAL ARTICLE
Denise D Correa, Jaya Satagopan, Axel Martin, Erica Braun, Maria Kryza-Lacombe, Kenneth Cheung, Ajay Sharma, Sofia Dimitriadoy, Kelli O'Connell, Siok Leong, Sasan Karimi, John Lyo, Lisa M DeAngelis, Irene Orlow
BACKGROUND: Patients with brain tumors treated with radiotherapy (RT) and chemotherapy (CT) often experience cognitive dysfunction. We reported that single nucleotide polymorphisms (SNPs) in the APOE, COMT, and BDNF genes may influence cognition in brain tumor patients. In this study, we assessed whether genes associated with late-onset Alzheimer's disease (LOAD), inflammation, cholesterol transport, dopamine and myelin regulation, and DNA repair may influence cognitive outcome in this population...
October 9, 2019: Neuro-oncology
#29
JOURNAL ARTICLE
Xi Chen, Aya Haggiagi, Efstathia Tzatha, Lisa M DeAngelis, Bianca Santomasso
OBJECTIVE: To report the electrodiagnostic features of immune checkpoint inhibitor (ICI)-related neuropathy. METHODS: We retrospectively reviewed clinical presentations and electrodiagnostic features of 23 patients studied after receiving immune checkpoint inhibitors (ICIs). The presentations for electrodiagnostic evaluation included an acute neuropathy or neuromuscular junction disorder. We applied established electrodiagnostic criteria for polyneuropathy and acute demyelinating neuropathy...
August 2019: Clinical Neurophysiology: Official Journal of the International Federation of Clinical Neurophysiology
#30
JOURNAL ARTICLE
Lisa M DeAngelis
No abstract text is available yet for this article.
April 2019: Lancet Neurology
#31
JOURNAL ARTICLE
Patrick Y Wen, Mehdi Touat, Brian M Alexander, Ingo K Mellinghoff, Shakti Ramkissoon, Christine S McCluskey, Kristine Pelton, Sam Haidar, Sankha S Basu, Sarah C Gaffey, Loreal E Brown, Juan Emmanuel Martinez-Ledesma, Shaofang Wu, Jungwoo Kim, Wei Wei, Mi-Ae Park, Jason T Huse, John G Kuhn, Mikael L Rinne, Howard Colman, Nathalie Y R Agar, Antonio M Omuro, Lisa M DeAngelis, Mark R Gilbert, John F de Groot, Timothy F Cloughesy, Andrew S Chi, Thomas M Roberts, Jean J Zhao, Eudocia Q Lee, Lakshmi Nayak, James R Heath, Laura L Horky, Tracy T Batchelor, Rameen Beroukhim, Susan M Chang, Azra H Ligon, Ian F Dunn, Dimpy Koul, Geoffrey S Young, Michael D Prados, David A Reardon, W K Alfred Yung, Keith L Ligon
PURPOSE: Phosphatidylinositol 3-kinase (PI3K) signaling is highly active in glioblastomas. We assessed pharmacokinetics, pharmacodynamics, and efficacy of the pan-PI3K inhibitor buparlisib in patients with recurrent glioblastoma with PI3K pathway activation. METHODS: This study was a multicenter, open-label, multi-arm, phase II trial in patients with PI3K pathway-activated glioblastoma at first or second recurrence. In cohort 1, patients scheduled for re-operation after progression received buparlisib for 7 to 13 days before surgery to evaluate brain penetration and modulation of the PI3K pathway in resected tumor tissue...
March 20, 2019: Journal of Clinical Oncology
#32
JOURNAL ARTICLE
Alexandra M Miller, Ronak H Shah, Elena I Pentsova, Maryam Pourmaleki, Samuel Briggs, Natalie Distefano, Youyun Zheng, Anna Skakodub, Smrutiben A Mehta, Carl Campos, Wan-Ying Hsieh, S Duygu Selcuklu, Lilan Ling, Fanli Meng, Xiaohong Jing, Aliaksandra Samoila, Tejus A Bale, Dana W Y Tsui, Christian Grommes, Agnes Viale, Mark M Souweidane, Viviane Tabar, Cameron W Brennan, Anne S Reiner, Marc Rosenblum, Katherine S Panageas, Lisa M DeAngelis, Robert J Young, Michael F Berger, Ingo K Mellinghoff
Diffuse gliomas are the most common malignant brain tumours in adults and include glioblastomas and World Health Organization (WHO) grade II and grade III tumours (sometimes referred to as lower-grade gliomas). Genetic tumour profiling is used to classify disease and guide therapy1,2 , but involves brain surgery for tissue collection; repeated tumour biopsies may be necessary for accurate genotyping over the course of the disease3-10 . While the detection of circulating tumour DNA (ctDNA) in the blood of patients with primary brain tumours remains challenging11,12 , sequencing of ctDNA from the cerebrospinal fluid (CSF) may provide an alternative way to genotype gliomas with lower morbidity and cost13,14 ...
January 2019: Nature
#33
JOURNAL ARTICLE
Robert M Samstein, Chung-Han Lee, Alexander N Shoushtari, Matthew D Hellmann, Ronglai Shen, Yelena Y Janjigian, David A Barron, Ahmet Zehir, Emmet J Jordan, Antonio Omuro, Thomas J Kaley, Sviatoslav M Kendall, Robert J Motzer, A Ari Hakimi, Martin H Voss, Paul Russo, Jonathan Rosenberg, Gopa Iyer, Bernard H Bochner, Dean F Bajorin, Hikmat A Al-Ahmadie, Jamie E Chaft, Charles M Rudin, Gregory J Riely, Shrujal Baxi, Alan L Ho, Richard J Wong, David G Pfister, Jedd D Wolchok, Christopher A Barker, Philip H Gutin, Cameron W Brennan, Viviane Tabar, Ingo K Mellinghoff, Lisa M DeAngelis, Charlotte E Ariyan, Nancy Lee, William D Tap, Mrinal M Gounder, Sandra P D'Angelo, Leonard Saltz, Zsofia K Stadler, Howard I Scher, Jose Baselga, Pedram Razavi, Christopher A Klebanoff, Rona Yaeger, Neil H Segal, Geoffrey Y Ku, Ronald P DeMatteo, Marc Ladanyi, Naiyer A Rizvi, Michael F Berger, Nadeem Riaz, David B Solit, Timothy A Chan, Luc G T Morris
Immune checkpoint inhibitor (ICI) treatments benefit some patients with metastatic cancers, but predictive biomarkers are needed. Findings in selected cancer types suggest that tumor mutational burden (TMB) may predict clinical response to ICI. To examine this association more broadly, we analyzed the clinical and genomic data of 1,662 advanced cancer patients treated with ICI, and 5,371 non-ICI-treated patients, whose tumors underwent targeted next-generation sequencing (MSK-IMPACT). Among all patients, higher somatic TMB (highest 20% in each histology) was associated with better overall survival...
February 2019: Nature Genetics
#34
JOURNAL ARTICLE
Babak B Navi, Anne S Reiner, Hooman Kamel, Costantino Iadecola, Peter M Okin, Scott T Tagawa, Katherine S Panageas, Lisa M DeAngelis
Cancer patients face an increased risk of arterial thromboembolism; however, it is uncertain when this excess risk begins. This study evaluated the risk of arterial thromboembolism before cancer diagnosis. Using the population-based Surveillance Epidemiology and End Results-Medicare linked dataset, we identified 374 331 patients ≥67 years of age with a new primary diagnosis of breast, lung, prostate, colorectal, bladder, uterine, pancreatic, gastric cancer, or non-Hodgkin lymphoma from 2005 through 2013...
February 21, 2019: Blood
#35
JOURNAL ARTICLE
Christian Grommes, Sarah S Tang, Julia Wolfe, Thomas J Kaley, Mariza Daras, Elena I Pentsova, Anna F Piotrowski, Jacqueline Stone, Andrew Lin, Craig P Nolan, Malbora Manne, Paolo Codega, Carl Campos, Agnes Viale, Alissa A Thomas, Michael F Berger, Vaios Hatzoglou, Anne S Reiner, Katherine S Panageas, Lisa M DeAngelis, Ingo K Mellinghoff
Ibrutinib is a first-in-class inhibitor of Bruton tyrosine kinase (BTK) and has shown single-agent activity in recurrent/refractory central nervous system (CNS) lymphoma. Clinical responses are often transient or incomplete, suggesting a need for a combination therapy approach. We conducted a phase 1b clinical trial to explore the sequential combination of ibrutinib (560 or 840 mg daily dosing) with high-dose methotrexate (HD-MTX) and rituximab in patients with CNS lymphoma (CNSL). HD-MTX was given at 3.5 g/m2 every 2 weeks for a total of 8 doses (4 cycles; 1 cycle = 28 days)...
January 31, 2019: Blood
#36
REVIEW
Christian Grommes, James L Rubenstein, Lisa M DeAngelis, Andres J M Ferreri, Tracy T Batchelor
Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma that affects the brain parenchyma, spinal cord, eyes, and cerebrospinal fluid without evidence of systemic, non-CNS involvement. PCNSL is uncommon and only a few randomized trials have been completed in the first-line setting. Over the past decades, the prognosis of PCNSL has improved, mainly due to the introduction and widespread use of high-dose methotrexate, which is now the backbone of all first-line treatment polychemotherapy regimens...
February 19, 2019: Neuro-oncology
#37
JOURNAL ARTICLE
Thomas Kaley, Mehdi Touat, Vivek Subbiah, Antoine Hollebecque, Jordi Rodon, A Craig Lockhart, Vicki Keedy, Franck Bielle, Ralf-Dieter Hofheinz, Florence Joly, Jean-Yves Blay, Ian Chau, Igor Puzanov, Noopur S Raje, Jurgen Wolf, Lisa M DeAngelis, Martina Makrutzki, Todd Riehl, Bethany Pitcher, Jose Baselga, David M Hyman
PURPOSE: BRAFV600 mutations are frequently found in several glioma subtypes, including pleomorphic xanthoastrocytoma (PXA) and ganglioglioma and much less commonly in glioblastoma. We sought to determine the activity of vemurafenib, a selective inhibitor of BRAFV600 , in patients with gliomas that harbor this mutation. PATIENTS AND METHODS: The VE-BASKET study was an open-label, nonrandomized, multicohort study for BRAFV600 -mutant nonmelanoma cancers. Patients with BRAFV600 -mutant glioma received vemurafenib 960 mg twice per day continuously until disease progression, withdrawal, or intolerable adverse effects...
October 23, 2018: Journal of Clinical Oncology
#38
JOURNAL ARTICLE
Han W Tun, Patrick B Johnston, Lisa M DeAngelis, Pamela J Atherton, Levi D Pederson, Patricia A Koenig, Craig B Reeder, Antonio M Padula Omuro, David Schiff, Brian O'Neill, Jose Pulido, Kurt A Jaeckle, Christian Grommes, Thomas E Witzig
The combination of pomalidomide (POM) and dexamethasone (DEX) was evaluated for relapsed/refractory primary central nervous system lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL) to determine the maximal tolerated dose (MTD) of POM as the primary objective, and overall response rate (ORR), progression-free survival (PFS), and safety profile as secondary objectives. A cohorts-of-3 study design was used with a dose-escalation schedule consisting of POM (3, 5, 7, or 10 mg) orally daily for 21 days every 28 days and DEX 40 mg orally every week...
November 22, 2018: Blood
#39
REVIEW
Maya S Graham, Lisa M DeAngelis
Primary central nervous system lymphoma (PCNSL) is an aggressive disease with previously poor prognosis. The advent of high-dose methotrexate-based induction regimens as well as use of consolidation therapy has greatly improved this prognosis in recent decades, but durable remission still eludes half of patients. In this review, we summarize the progress made in the treatment of PCNSL as well as the challenges that remain, with a focus on defining optimal induction and consolidation regimens, including the promise of developing biotherapies...
September 2018: Best Practice & Research. Clinical Haematology
#40
LETTER
Anne S Reiner, Debra A Goldman, Eli L Diamond, Lisa M DeAngelis, Viviane Tabar, Katherine S Panageas
No abstract text is available yet for this article.
September 2018: World Neurosurgery
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
